| [1] |
Esposito A, Criscitiello C, Locatelli M, et al. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies [J]. Pharmacol Ther, 2016, 157: 120-124.
|
| [2] |
Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA [J]. Cancer Discov, 2014, 4(6): 650-661.
|
| [3] |
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J]. N Engl J Med, 2004, 351(8): 781-791.
|
| [4] |
Nolé F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications [J]. Ann Oncol, 2008, 19(5): 891-897.
|
| [5] |
Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival [J]. Clin Cancer Res, 2006, 12(14 Pt 1): 4218-4224.
|
| [6] |
Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis [J]. Cell, 2014, 158(5): 1110-1122.
|
| [7] |
De Luca F, Rotunno G, Salvianti F, et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer [J]. Oncotarget, 2016, 7(18): 26 107-26 119.
|
| [8] |
US Food and Drug Administration. Medical devices. CellSearch epithelial cell kit/CellSpotter analyzer—K031588.Accessed Feb 25, 2014 [EB/OL]．[2017-01-01]．
URL
|
| [9] |
Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study [J]. Lancet Oncol, 2012, 13(7): 688-695.
|
| [10] |
Bidard FC, Mathiot C, Delaloge S, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer [J]. Ann Oncol, 2010, 21(4): 729-733.
|
| [11] |
Rack B, Schindlbeck C, Juckstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients [J]. J Natl Cancer Inst, 2014, 106(5): dju066.
|
| [12] |
Thill M, Liedtke C, AGO Breast Committee. AGO Recommendations for the diagnosis and treatment of patients with advanced and metastatic breast cancer: update 2016 [J]. Breast Care (Basel), 2016, 11(3): 216-222.
|
| [13] |
Riethdorf S, Müller V, Loibl S, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant "Geparquattro" trial [J]. Clin Cancer Res, 2017, 23(18): 5384-5393.
|
| [14] |
Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer [J]. J Clin Oncol, 2009, 27(31): 5153-5159.
|
| [15] |
De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer [J]. Ann Oncol, 2010, 21(1): 33-39.
|
| [16] |
Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition [J]. Science, 2013, 339(6119): 580-584.
|
| [17] |
Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase Ⅱ randomized trial [J]. Clin Cancer Res, 2008, 14(21): 7004-7010.
|
| [18] |
Azim HA Jr, Rothé F, Aura CM, et al. Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase Ⅲ trial [J]. Breast, 2013, 22(6): 1060-1065.
|
| [19] |
郝帅，田武国，高博，等. 循环肿瘤细胞检测在乳腺癌新辅助化疗疗效评估中的价值 [J/CD]. 中华乳腺病杂志，2017，11(1)：6-12.
|
| [20] |
Kasimir-Bauer S, Bittner AK, König L, et al. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy [J]. Breast Cancer Res, 2016, 18(1): 20.
|
| [21] |
Hall C, Karhade M, Laubacher B, et al. Circulating tumor cells after neoadjuvant chemotherapy in stage Ⅰ－Ⅲ triple-negative breast cancer [J]. Ann Surg Oncol, 2015, 22 Suppl 3: S552-558.
|
| [22] |
Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility [J]. Science, 2014, 345(6193): 216-220.
|
| [23] |
Maheswaran S, Haber DA. Ex vivo culture of CTCs: An emerging resource to guide cancer therapy [J]. Cancer Res, 2015, 75(12): 2411-2415.
|
| [24] |
Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500 [J]. J Clin Oncol, 2014, 32(31): 3483-3489.
|
| [25] |
Institut Curie.Circulating tumor cells to guide chemotherapy for metastatic breast cancer (CirCé01) [EB/OL]．[2017-01-01].
URL
|
| [26] |
Janni W. DETECT Ⅲ - A multicenter, phase Ⅲ study to compare standard therapy＋/- lapatinib in HER2-ve MBC-patients with HER2＋ve CTCs[EB/OL]. [2017-01-01]．
URL
|
| [27] |
Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer [J]. N Engl J Med, 2008, 358(13): 1409-1411.
|
| [28] |
Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25): 3366-3373.
|
| [29] |
Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses [J]. Proc Natl Acad Sci U S A, 2004, 101(25): 9393-9398.
|
| [30] |
Flores LM, Kindelberger DW, Ligon AH, et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer [J]. Br J Cancer, 2010, 102(10): 1495-1502.
|
| [31] |
Tewes M, Aktas B, Welt A, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies [J]. Breast Cancer Res Treat, 2009, 115(3): 581-590.
|
| [32] |
Georgoulias V, Bozionelou V, Agelaki S, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase Ⅱ study [J]. Ann Oncol, 2012, 23(7): 1744-1750.
|
| [33] |
European Organisation for Research and Treatment of Cancer. Efficacy study of herceptin to treat HER2-negative CTC breast cancer (TREAT-CTC)[EB/OL]. [2017-01-01].
URL
|
| [34] |
Jordan NV, Bardia A, Wittner BS, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells [J]. Nature, 2016, 537(7618): 102-106.
|
| [35] |
Schramm A, Friedl TW, Schochter F, et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program [J]. Arch Gynecol Obstet, 2016, 293(2): 271-281.
|
| [36] |
Institut Curie. Medico-economic interest of taking into account circulating tumor cells (CTC) to determine the kind of first line treatment for metastatic, hormone-receptors positive, breast cancers[EB/OL]. [2017-01-01].
URL
|
| [37] |
Hart CD, Migliaccio I, Malorni L, et al. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer [J]. Nat Rev Clin Oncol, 2015, 12(9): 541-552.
|
| [38] |
Paoletti C, Muniz MC, Thomas DG, et al. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer [J]. Clin Cancer Res, 2015, 21(11): 2487-2498.
|
| [39] |
Paoletti C, Larios JM, Muñiz MC, et al. Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance [J]. Mol Oncol, 2016, 10(7): 1078-1085.
|
| [40] |
Paolillo C, Mu Z, Rossi G, et al. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells [J]. Clin Cancer Res, 2017, 23(20): 6086-6093.
|
| [41] |
Miyamoto DT, Zheng Y, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance [J]. Science, 2015, 349(6254): 1351-1356.
|
| [42] |
Kidess E, Jeffrey SS. Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis? [J]. Genome Med, 2013, 5(8): 70.
|
| [43] |
Pantel K, Alix-Panabières C. Real-time liquid biopsy in cancer patients: fact or fiction? [J]. Cancer Res, 2013, 73(21): 6384-6388.
|
| [44] |
Jiang ZF, Cristofanilli M, Shao ZM, et al. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCS G004): a multicenter, double-blind, prospective trial [J]. Ann Oncol, 2013, 24(11): 2766-2772.
|
| [45] |
Zhang S, Li L, Wang T, et al. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients [J]. BMC Cancer, 2016, 16: 526.
|
| [46] |
Liu Y, Liu Q, Wang T, et al. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker [J]. BMC Cancer, 2013, 13: 202.
|
| [47] |
Guan X, Ma F, Liu S, et al. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells [J]. Oncotarget, 2016, 7(40): 65 993-66 002.
|
| [48] |
Gong C, Liu B, Yao Y, et al. Potentiated DNA damage response in circulating breast tumor cells confers resistance to chemotherapy [J]. J Biol Chem, 2015, 290(24): 14 811-14 825.
|